Evidence map›Paper›PMID 37469133›Full record

ArticleThe Journal of infectious diseases2023

A Single-Dose Intranasal Combination Panebolavirus Vaccine.

Delphine C Malherbe, J Brian Kimble, Caroline Atyeo, Stephanie Fischinger, Michelle Meyer, S Gabrielle Cody, Matthew Hyde, Galit Alter, Alexander Bukreyev

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Marburg Virus Medical Countermeasures.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Delphine C MalherbeDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
J Brian KimbleDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Caroline AtyeoRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
Stephanie FischingerRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
Michelle MeyerDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
S Gabrielle CodyDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Matthew HydeGalveston National Laboratory, Galveston, Texas, USA.
Galit AlterRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
Alexander BukreyevDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.ORCID 0000-0002-0342-4824
Galveston College · USRagon Institute of MGH, MIT and Harvard · USThe University of Texas Medical Branch at Galveston · US

Funding

Broadly Specific Needle-Free Vaccines against Emerging and Biothreat VirusesR01AI102887 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BUKREYEV, ALEXANDER · 2013 to 2017
$3.5M
NIAID NIH HHS R01 AI102887NIH HHS 1R01AI102887-01A1
6 · The paper itself

Abstract

backgroundEbolaviruses Ebola (EBOV), Sudan (SUDV), and Bundibugyo (BDBV) cause severe human disease, which may be accompanied by hemorrhagic syndrome, with high case fatality rates. Monovalent vaccines do not offer cross-protection against these viruses whose endemic areas overlap. Therefore, development of a panebolavirus vaccine is a priority. As a vaccine vector, human parainfluenza virus type 3 (HPIV3) has the advantages of needle-free administration and induction of both systemic and local mucosal antibody responses in the respiratory tract.

methodsTo minimize the antivector immunity, genes encoding the HPIV3 envelope proteins F and HN were removed from the vaccine constructs, resulting in expression of only the ebolavirus envelope protein-glycoprotein. These second-generation vaccine constructs were used to develop a combination vaccine against EBOV, SUDV, and BDBV.

resultsA single intranasal vaccination of guinea pigs or ferrets with the trivalent combination vaccine elicited humoral responses to each of the targeted ebolaviruses, including binding and neutralizing antibodies, as well as Fc-mediated effector functions. This vaccine protected animals from death and disease caused by lethal challenges with EBOV, SUDV, or BDBV.

conclusionsThe combination vaccine elicited protection that was comparable to that induced by the monovalent vaccines, thus demonstrating the value of this combination trivalent vaccine.

Indexed as

Ebola VaccinesEbolavirusHemorrhagic Fever, EbolaAnimalsAntibodies, NeutralizingAntibodies, ViralFerretsGuinea PigsHumansVaccines, CombinedAntibodies, NeutralizingAntibodies, ViralEbola VaccinesVaccines, CombinedEbola virusintranasal vaccinationvaccine

Identifiers

PMID37469133
PMCPMC10651208
OpenAlexW4384819969

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.